MiniMed Group (MMED) Goldman Sachs 47th Annual Global Healthcare Conference 2026 summary

Key conference takeaways

• Automated insulin delivery (AID) is the primary growth area, with significant market headroom, especially as automation, not just CGM, is emphasized for therapy advancement.

• Recent product launches include MiniMed Go (smart MDI solution) and Flex, both receiving strong interest and positive feedback at ADA.

• The company is positioning itself as a growth story, having overcome past regulatory and product challenges, and now boasts a robust pipeline for all stages of diabetes management.

• Unique integrated system (CGM, pumps, algorithm) and a razor blade business model support global growth, with a direct commercial presence in 80 countries.

• GLP-1s are seen as complementary, not competitive, with AID systems, as insulin dependency remains for many patients.

U.S. and global growth strategy

• Four major U.S. product launches are planned within the next year, with significant hardware, software, and algorithm improvements.

• Expansion into the pharmacy channel enhances scalability and patient access, leveraging both DME and pharmacy models.

• International growth has been driven by early product launches, with the U.S. now catching up as new products roll out.

• The commercial team and support infrastructure are already in place globally, enabling rapid execution without the need for new sales force buildout.

• Direct contracts with payers and PBMs allow for stable pricing across DME and pharmacy channels, countering concerns about price erosion.

Product and technology differentiation

• The company maintains a closed ecosystem, integrating CGM, pumps, and software for a seamless user experience, prioritizing simplicity and automation.

• New products like Fit and Flex focus on modern form factors and usability, shifting market focus from hardware to clinical outcomes and algorithm performance.

• The next-generation algorithm, Vivera, is in pivotal trials and aims to deliver fully closed-loop therapy for both type 1 and type 2 diabetes.

• Fit is expected to be filed in the fall, with launch capacity for 20,000 patients and both type 1 and type 2 indications, available through pharmacy only.

• Scale in manufacturing, shared technology platforms, and a global commercial footprint are seen as key competitive advantages.